Azatilizumab (Niktimvo) is a new option for the treatment of cGVHD, complete analysis of dosage and usage

Azatilimab (axatilimab-csfr, trade nameNiktimvo) as an innovative colony-stimulating factor-1 Receptor (CSF-1R) blockers bring new treatment hope to adults and children with chronic graft-versus-host disease (cGVHD) weighing at least 40kg. These patients often require new treatment options after failure of at least two systemic therapies.

Azatilizumab is a monoclonal antibody whose unique mechanism of action is its ability to bind to and block the CSF-1R receptor on immune system cells (such as monocytes and macrophages). Through this effect, azatilizumab can effectively reduce the levels of pro-inflammatory and pro-fibrotic monocytes and monocyte-derived macrophages, while inhibiting the activity of pathogenic macrophages in tissues, thereby alleviating the symptoms of cGVHD.

In terms of medication, azatilizumab is administered by intravenous infusion, once every 2 weeks, and each infusion lasts 30 minutes. To ensure patient safety and comfort, healthcare providers may prescribe medications such as diphenhydramine (an antihistamine) and acetaminophen (an antipyretic) before each infusion to prevent possible infusion-related reactions.

In addition, the medical team will conduct regular blood tests and closely monitor the patient's physical condition and side effects to ensure the safety and effectiveness of the treatment. The recommended dose of azatilizumab is 0.3 mg/kg every 2 weeks, with a maximum dose not to exceed 35 mg. To facilitate dosage adjustment, the drug is available in three single-dose vials: 9 mg/0.18 ml, 22 mg >mg/0.44ml and 50mg/ml solutions to meet patients with different weights and treatment needs.

During a specific treatment, the health care provider will determine the total number and duration of treatments based on the patient's specific circumstances, including weight, severity of illness, and response to treatment. Patients need to receive treatment strictly in accordance with medical instructions and be closely observed during the infusion process for any infusion-related reactions or other side effects.

With standardized dosage and close medical monitoring, azatilizumab provides a safe and effective treatment option for cGVHD patients. If you have questions about the dosage, administration or any other aspect of azatilizumab, it is recommended that you consult your primary care physician.

Reference link:https://www.drugs.com/niktimvo.html